| The Beaufour Ipsen Group has obtained authorisation to market a new sustained-release injection formulation of lanreotide, Somatuline Autogel, in the UK, France and Portugal. |   |
Somatuline Autogel is used to control growth hormone (GH) levels in people with acromegaly and also to provide symptomatic relief for patients with neuroendocrine tumours. Clinical studies have shown that Somatuline Autogel provides sustained drug release for at least 28 days.
Source: Ipsen
